Cargando…
Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure
BACKGROUND: Pulmonary tuberculosis (TB) with detectable Mycobacterium tuberculosis in the sputum is a major source of transmission. In resource limited TB endemic settings, cure is declared through sputum smear examination for acid fast bacilli without performing culture. This may lead to erroneous...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822412/ https://www.ncbi.nlm.nih.gov/pubmed/31666021 http://dx.doi.org/10.1186/s12879-019-4561-7 |
_version_ | 1783464329589293056 |
---|---|
author | Ambreen, Atiqa Jamil, Muhammad Rahman, Mohammad Aqeel ur Mustafa, Tehmina |
author_facet | Ambreen, Atiqa Jamil, Muhammad Rahman, Mohammad Aqeel ur Mustafa, Tehmina |
author_sort | Ambreen, Atiqa |
collection | PubMed |
description | BACKGROUND: Pulmonary tuberculosis (TB) with detectable Mycobacterium tuberculosis in the sputum is a major source of transmission. In resource limited TB endemic settings, cure is declared through sputum smear examination for acid fast bacilli without performing culture. This may lead to erroneous treatment outcomes as viable bacteria may be missed due to the low sensitivity of direct smear method. The aim of this study was to investigate if sterilizing cure is achieved among the new pulmonary TB cases declared cured by sputum smear conversion and to evaluate the impact of addition of ethambutol in the continuation phase in achieving it. METHODS: New sputum smear-positive pulmonary TB patients registered at a tertiary care hospital in Pakistan from November 2013 to March 2014 were followed under standard Directly Observed Treatment Short Course strategy for 6 months. Half of these patients received ethambutol in addition to isoniazid and rifampicin in the continuation phase. Sputum specimens were examined on microscopy at 2 months and at the end of treatment. Sputa of patients with negative direct smear examination at the end of treatment were cultured. RESULTS: Among 5746 TB suspects, 1595 were new sputum smear positive pulmonary TB cases, and 533 were registered at our hospital. Among these, 504 converted sputum negative at 2 months and 348 converted at the end of 6 months of treatment and were declared cured. Sputa of 204/348 patients were cultured, and 12/204 (6%) were culture-positive. Culture positivity at 6 months was not associated with bacterial load, smoking, diabetes, presence of cavities, history of contact with TB patients, age, sex, socioeconomic status, or addition of ethambutol in the continuation phase. CONCLUSION: Viable cultivable bacilli were detected in 6% of cured patients, which would have significant impact on the control of TB. This highlights the need for an inexpensive and accurate surrogate marker for culture as it is not feasible to perform culture in routine for monitoring treatment response in the low-resource settings. The treatment outcome did not improve by addition of ethambutol emphasizing the need to find the optimal duration of treatment for individual or carefully selected groups of patients. |
format | Online Article Text |
id | pubmed-6822412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68224122019-11-06 Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure Ambreen, Atiqa Jamil, Muhammad Rahman, Mohammad Aqeel ur Mustafa, Tehmina BMC Infect Dis Research Article BACKGROUND: Pulmonary tuberculosis (TB) with detectable Mycobacterium tuberculosis in the sputum is a major source of transmission. In resource limited TB endemic settings, cure is declared through sputum smear examination for acid fast bacilli without performing culture. This may lead to erroneous treatment outcomes as viable bacteria may be missed due to the low sensitivity of direct smear method. The aim of this study was to investigate if sterilizing cure is achieved among the new pulmonary TB cases declared cured by sputum smear conversion and to evaluate the impact of addition of ethambutol in the continuation phase in achieving it. METHODS: New sputum smear-positive pulmonary TB patients registered at a tertiary care hospital in Pakistan from November 2013 to March 2014 were followed under standard Directly Observed Treatment Short Course strategy for 6 months. Half of these patients received ethambutol in addition to isoniazid and rifampicin in the continuation phase. Sputum specimens were examined on microscopy at 2 months and at the end of treatment. Sputa of patients with negative direct smear examination at the end of treatment were cultured. RESULTS: Among 5746 TB suspects, 1595 were new sputum smear positive pulmonary TB cases, and 533 were registered at our hospital. Among these, 504 converted sputum negative at 2 months and 348 converted at the end of 6 months of treatment and were declared cured. Sputa of 204/348 patients were cultured, and 12/204 (6%) were culture-positive. Culture positivity at 6 months was not associated with bacterial load, smoking, diabetes, presence of cavities, history of contact with TB patients, age, sex, socioeconomic status, or addition of ethambutol in the continuation phase. CONCLUSION: Viable cultivable bacilli were detected in 6% of cured patients, which would have significant impact on the control of TB. This highlights the need for an inexpensive and accurate surrogate marker for culture as it is not feasible to perform culture in routine for monitoring treatment response in the low-resource settings. The treatment outcome did not improve by addition of ethambutol emphasizing the need to find the optimal duration of treatment for individual or carefully selected groups of patients. BioMed Central 2019-10-30 /pmc/articles/PMC6822412/ /pubmed/31666021 http://dx.doi.org/10.1186/s12879-019-4561-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ambreen, Atiqa Jamil, Muhammad Rahman, Mohammad Aqeel ur Mustafa, Tehmina Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure |
title | Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure |
title_full | Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure |
title_fullStr | Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure |
title_full_unstemmed | Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure |
title_short | Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure |
title_sort | viable mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822412/ https://www.ncbi.nlm.nih.gov/pubmed/31666021 http://dx.doi.org/10.1186/s12879-019-4561-7 |
work_keys_str_mv | AT ambreenatiqa viablemycobacteriumtuberculosisinsputumafterpulmonarytuberculosiscure AT jamilmuhammad viablemycobacteriumtuberculosisinsputumafterpulmonarytuberculosiscure AT rahmanmohammadaqeelur viablemycobacteriumtuberculosisinsputumafterpulmonarytuberculosiscure AT mustafatehmina viablemycobacteriumtuberculosisinsputumafterpulmonarytuberculosiscure |